# A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

> **NCT06843967** · PHASE1,PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 54 (estimated)

## Conditions studied

- Well Differentiated Liposarcoma
- Dedifferentiated Liposarcoma
- Liposarcoma
- Myxoid Liposarcoma
- Round Cell Liposarcoma
- Myxoid Pleomorphic Liposarcoma
- Pleomorphic Liposarcoma
- Unresectable Liposarcoma
- Unresectable Dedifferentiated Liposarcoma

## Interventions

- **DRUG:** Mirdametinib
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT06843967
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-19
- **Primary completion:** 2028-08-19
- **Final completion:** 2028-08-19
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06843967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06843967, "A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06843967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*